Brazilian Neurodegeneration Biotech Companies

Migration, Crosslink

📖

Brazilian Neurodegeneration Biotech Companies

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-brazilian-neurodegenerati

📖 Wiki Page

company3277 wordssynced 2026-04-02

Overview

flowchart TD companies_brazilian_neurodegen["Brazilian Neurodegeneration Biotech Companies"] style companies_brazilian_neurodegen fill:#4fc3f7,stroke:#333,color:#000 companies_brazilian__0["Key Companies"] companies_brazilian_neurodegen -->|"includes"| companies_brazilian__0 style companies_brazilian__0 fill:#81c784,stroke:#333,color:#000 companies_brazilian__1["Recepta Biopharma"] companies_brazilian_neurodegen -->|"includes"| companies_brazilian__1 style companies_brazilian__1 fill:#ef5350,stroke:#333,color:#000 companies_brazilian__2["Brazilian Brain Institute IBN"] companies_brazilian_neurodegen -->|"includes"| companies_brazilian__2 style companies_brazilian__2 fill:#ffd54f,stroke:#333,color:#000 companies_brazilian__3["Herbarium Grupo Boticrio"] companies_brazilian_neurodegen -->|"includes"| companies_brazilian__3 style companies_brazilian__3 fill:#ce93d8,stroke:#333,color:#000 companies_brazilian__4["Cryopraxis"] companies_brazilian_neurodegen -->|"includes"| companies_brazilian__4 style companies_brazilian__4 fill:#4fc3f7,stroke:#333,color:#000 companies_brazilian__5["Astellas Brazil"] companies_brazilian_neurodegen -->|"includes"| companies_brazilian__5 style companies_brazilian__5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Brazilian biotechnology companies are increasingly contributing to neurodegenerative disease research and therapy development. With a growing academic ecosystem, particularly in São Paulo, Rio de Janeiro, and Minas Gerais, Brazil has emerged as a regional hub for neuroscience research in Latin America. Several Brazilian biotech companies and academic spin-outs are developing treatments for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions["@brazilian2024"].

The burden of neurodegenerative diseases in Brazil is substantial. Recent epidemiological studies estimate that approximately 1.8 million people in Brazil are living with dementia, with Alzheimer's disease representing approximately 60-70% of these cases. Parkinson's disease affects approximately 200,000-250,000 Brazilians, with prevalence expected to increase significantly as the population ages["@grimmer2024"]. The growing awareness of these conditions, combined with expanding clinical research infrastructure, has created opportunities for Brazilian biotech companies to address significant unmet medical needs.

This page covers Brazilian biotech companies focused on neurodegeneration, their therapeutic approaches, research collaborations, and development status. The Brazilian neurodegenerative disease biotech landscape represents an emerging but rapidly developing sector with unique strengths in stem cell therapy, natural product discovery, and clinical trial execution.

Key Companies

Recepta Biopharma

Location: São Paulo, Brazil
Focus: Antibody-based therapies for oncology and neuroscience
Neurodegeneration focus: Neuroinflammatory pathways in Alzheimer's disease
Approach: Monoclonal antibodies targeting inflammatory mediators
Status: Research and early development
Notes: Originally oncology-focused, expanded into neuroscience[@recepta2024]

Recepta Biopharma represents one of the most advanced Brazilian biotech companies with explicit neurodegeneration programs. Founded in 2006 in São Paulo, Recepta initially focused on developing antibody-based therapeutics for cancer. The company's expansion into neuroscience was motivated by the growing burden of Alzheimer's disease in Brazil and the recognition that neuroinflammation represents a promising therapeutic target that aligns with Recepta's antibody development capabilities.

The company's neurodegeneration strategy focuses on targeting key inflammatory mediators in the Alzheimer's disease brain. Their lead program targets the NLRP3 inflammasome, a key driver of neuroinflammation that has been implicated in Alzheimer's disease progression. Preclinical studies in mouse models have demonstrated that anti-NLRP3 antibodies can reduce microglial activation and improve cognitive performance in APP/PS1 transgenic mice[@menezes2024].

Recepta has established collaborations with the University of São Paulo's Department of Neurology and the Brazilian Brain Institute to support its neuroscience programs. The company has received funding from FAPESP (São Paulo Research Foundation) through its Innovative Research in Small Business program to support its neurodegeneration pipeline development.

Brazilian Brain Institute (IBN)

Location: São Paulo, Brazil
Focus: Neuroscience research and therapy development
Neurodegeneration focus: Alzheimer's, Parkinson's, and stroke
Approach: Stem cell therapy, neurotrophic factors
Status: Research institution with clinical translation focus
Notes: Academic spin-out from University of São Paulo

The Brazilian Brain Institute (Instituto Brasileiro de Neurociência, IBN) is a leading neuroscience research institution in Brazil that has developed significant capabilities in neurodegenerative disease research and cell-based therapy development[@brazilian2024a]. Founded as a spin-out from the University of São Paulo, IBN brings together leading researchers from multiple disciplines to advance understanding and treatment of neurological disorders.

IBN's neurodegeneration research program spans multiple therapeutic modalities, with particular emphasis on stem cell therapy and neurotrophic factor approaches. The institute's stem cell research focuses on mesenchymal stem cells (MSCs) derived from adipose tissue and bone marrow, evaluating their potential for neuroprotection and immunomodulation in Alzheimer's and Parkinson's disease models[@shinomoto2023].

In Parkinson's disease, IBN researchers have conducted preclinical studies demonstrating that MSC transplantation can protect dopaminergic neurons in the substantia nigra and improve motor function in 6-hydroxydopamine lesioned rats. The institute has also explored the use of neurotrophic factors including GDNF and BDNF to support neuron survival and function.

IBN has established partnerships with several international research institutions and has participated in multicenter clinical trials for neurodegenerative diseases. The institute's clinical translation program aims to advance promising cell-based therapies from preclinical development to clinical testing.

Herbarium (Grupo Boticário)

Location: São Paulo, Brazil
Focus: Phytopharmaceuticals and natural products
Neurodegeneration focus: Neuroprotective natural compounds
Approach: Plant-derived neuroprotective agents
Status: Research and product development
Notes: Part of Grupo Boticário, exploring natural products for brain health

Herbarium, the pharmaceutical division of Grupo Boticário, represents a unique approach to neurodegeneration drug discovery in Brazil. Leveraging Brazil's extraordinary biodiversity, Herbarium's research program focuses on identifying and characterizing neuroprotective compounds from native plant species[@martins2024].

The company's natural product screening program has identified several promising leads from Brazilian flora. Research conducted in collaboration with the University of Campinas has characterized neuroprotective properties of extracts from species including Handroanthus impetiginosus (Brazilian purple trumpet tree) and Baccharis dracunculus. These extracts have demonstrated antioxidant, anti-inflammatory, and anti-amyloid activities in in vitro assays.

Herbarium's drug discovery approach combines traditional ethnobotanical knowledge with modern pharmaceutical science. The company's team of natural product chemists works closely with neuroscientists to bioassay-guided fractionate active extracts and identify individual compounds responsible for neuroprotective effects. This approach has yielded several natural product scaffolds that are now being optimized through medicinal chemistry programs.

The company's neurodegeneration portfolio includes both nutraceutical and pharmaceutical candidates. The nutraceutical division markets brain health supplements containing standardized botanical extracts, while the pharmaceutical division advances lead compounds through preclinical development toward clinical trials.

Cryopraxis

Location: Rio de Janeiro, Brazil
Focus: Cell therapy and cryopreservation
Neurodegeneration focus: Stem cell therapies for neurological disorders
Approach: Mesenchymal stem cell therapy
Status: Clinical development
Notes: Partnered with international pharma companies

Cryopraxis is a Brazilian biotechnology company specializing in cell therapy and stem cell cryopreservation. Founded in 2008 in Rio de Janeiro, the company has developed expertise in mesenchymal stem cell (MSC) manufacturing and has established a clinical-stage program in neurological disorders.

The company's lead product is a cryopreserved MSC formulation designated CPX-001. In preclinical studies, CPX-001 demonstrated neuroprotective effects in models of both Alzheimer's disease and Parkinson's disease. In Alzheimer's models, MSC treatment reduced amyloid plaque burden and improved cognitive performance. In Parkinson's models, the cells protected dopaminergic neurons and improved motor function.

Cryopraxis has completed Phase 1 clinical trials evaluating CPX-001 in patients with Parkinson's disease. The study, conducted at several Brazilian clinical sites, demonstrated the safety and tolerability of intrathecal MSC administration. A Phase 2 trial in patients with early-stage Parkinson's disease is planned to begin in 2025, evaluating both safety and preliminary efficacy endpoints.

The company has established partnerships with international pharmaceutical companies for both funding and commercialization rights. These partnerships provide Cryopraxis with access to global markets and additional expertise in clinical development and regulatory affairs.

Astellas Brazil

Location: São Paulo, Brazil
Focus: Pharmaceutical development
Neurodegeneration focus: Clinical trials for CNS disorders
Approach: Clinical development partnerships
Status: Clinical trials ongoing

Astellas Pharma Brazil operates as the local subsidiary of the global pharmaceutical company, hosting clinical trials for neurodegenerative disease therapeutics. The company has established a network of clinical sites across Brazil and has participated in multiple Phase 2 and Phase 3 trials for Alzheimer's and Parkinson's disease drugs.

Brazil represents an important region for Astellas's global clinical development program. The country's large patient population, well-established neurology centers, and regulatory pathways through ANVISA (Brazilian Health Regulatory Agency) enable efficient trial execution. Astellas has conducted trials for its pipeline of Alzheimer's disease modulators and Parkinson's disease treatments in Brazilian patient populations.

Latin American Neurodegeneration Research Network (LANDRn)

While not a company per se, this consortium merits mention as a key organization advancing neurodegenerative disease research in Brazil. LANDRn coordinates multi-center clinical studies across Latin America, including Brazil, Argentina, Chile, and Colombia. The network has established standardized protocols for patient assessment and biomarker collection, enabling cross-border collaboration and data sharing[@barroso2023].

Academic Research Centers

Brazil's academic research institutions form the foundation of the country's neurodegenerative disease research ecosystem. These institutions both generate new knowledge and provide trained researchers for the biotech sector.

University of São Paulo (USP) - Department of Neurology

The University of São Paulo's Department of Neurology represents Brazil's leading center for neurodegenerative disease research. Faculty members conduct research across Alzheimer's disease, Parkinson's disease, and related disorders, with particular strength in biomarker development and clinical characterization.

Research Areas:

Alzheimer's biomarkers: USP researchers have developed CSF and blood-based biomarker assays for Alzheimer's disease diagnosis and progression monitoring. Studies in Brazilian patient populations have characterized the performance of Aβ42, total tau, and phosphorylated tau biomarkers in the local context[@silva2023].
Parkinson's genetics: Genetic studies have characterized the frequency of known PD genetic risk factors in Brazilian populations, identifying both common variants and rare mutations in GBA, LRRK2, and SNCA genes.
Clinical trials: USP serves as a leading clinical trial site for international pharmaceutical companies, participating in studies for disease-modifying therapies in both AD and PD.

Collaborations: USP maintains active collaborations with international consortia including DIAN (Dominantly Inherited Alzheimer Network) and the Global Parkinson's Genetics Program (GP2). These partnerships provide access to cutting-edge research protocols and enable Brazilian researchers to contribute to global knowledge generation.

Federal University of Rio de Janeiro (UFRJ) - Neuroscience Institute

The Federal University of Rio de Janeiro's Institute of Neuroscience (INC) conducts fundamental and translational research on neurodegenerative diseases. The institute's research programs emphasize neuroprotection and neuroplasticity mechanisms.

Research Focus:

Neuroprotection mechanisms: Studies on molecular pathways underlying neuron survival, including autophagy, mitochondrial function, and oxidative stress responses.
Parkinson's disease models: Development and characterization of complementary animal models of Parkinson's disease, including toxin-based and genetic models.
Therapeutic candidates: Identification and characterization of small molecules with neuroprotective properties, including both synthetic compounds and natural products.

Output: UFRJ researchers have published extensively on neuroprotective mechanisms and have contributed to the identification of novel therapeutic targets. The institute maintains a strong pipeline of basic science discoveries that can be translated into therapeutic development programs.

Federal University of Minas Gerais (UFMG) - Neurology Department

The Federal University of Minas Gerais in Belo Horizonte has developed a strong clinical research program in neurodegenerative diseases, with particular emphasis on cognitive disorders and movement disorders.

Research Areas:

Cognitive disorders: Clinical characterization of dementia subtypes in Brazilian populations, including epidemiological studies and validation of cognitive assessment instruments.
Movement disorders: Research on Parkinson's disease and other movement disorders, including studies on non-motor symptoms and treatment outcomes.
Clinical research: Execution of clinical trials and observational studies in partnership with pharmaceutical companies and international research networks.

Output: UFMG researchers have contributed significant epidemiological data on neurodegenerative disease prevalence and incidence in Brazil, informing healthcare planning and policy development.

Therapeutic Approaches

Stem Cell Therapy

Brazilian companies and academic institutions are actively developing stem cell-based approaches for neurodegenerative diseases. This therapeutic modality offers potential for both neuroprotection and cell replacement strategies[@shinomoto2023].

Mesenchymal Stem Cells (MSCs):
MSCs represent the most advanced stem cell therapy approach in Brazil. Companies including Cryopraxis and the Brazilian Brain Institute have developed MSC-based products for neurological disorders. The mechanisms of action include:

Immunomodulation: MSCs can modulate microglial activation and reduce neuroinflammation
Neurotrophic support: MSCs secrete neurotrophic factors including BDNF, GDNF, and NGF that support neuron survival
Paracrine signaling: MSCs release extracellular vesicles containing bioactive molecules that promote tissue repair

Neural Stem Cells:
Research groups at USP and other institutions are developing neural stem cell approaches for cell replacement in Parkinson's disease. This strategy aims to replace lost dopaminergic neurons through transplantation of differentiated neural stem cells.

Induced Pluripotent Stem Cells (iPSCs):
Several Brazilian research groups have established iPSC programs for disease modeling and drug screening. iPSCs derived from patients with familial Alzheimer's or Parkinson's disease enable study of disease mechanisms in relevant cell types and screening of therapeutic compounds.

Natural Products

Brazil's exceptional biodiversity provides unique opportunities for drug discovery in neurodegeneration[@martins2024]. The country's flora includes over 55,000 documented species, many of which have been used in traditional medicine and represent potential sources of neuroprotective compounds.

Amazonian Plants:
The Amazon rainforest contains numerous plant species with documented or suspected neuroactive properties. Research programs have identified:

Alkaloids with cholinesterase inhibitory activity
Flavonoids with antioxidant and anti-inflammatory properties
Terpenoids with neuroprotective effects in cellular models

Atlantic Forest Species:
Plants from the Atlantic Forest biome have also been investigated for neuroprotective potential. Species from genera including Baccharis, Cordia, and Anacardium have demonstrated activity in neurodegeneration models.

Traditional Medicine Integration:
Brazilian researchers are working to integrate traditional knowledge from indigenous communities with modern drug development approaches. This includes documentation of traditional uses, scientific validation of bioactivity, and development of standardized botanical products.

Biomarker Development

Brazilian researchers are contributing to biomarker development for neurodegenerative diseases, with efforts focused on both validation of established biomarkers and discovery of novel markers[@silva2023].

CSF Biomarkers:
Studies at USP and other institutions have validated CSF Aβ42, total tau, and phosphorylated tau as diagnostic biomarkers in Brazilian populations. These studies have characterized the performance of these markers in the context of local clinical practice and healthcare infrastructure.

Blood-Based Biomarkers:
Emerging blood-based biomarker technologies are being evaluated in Brazilian cohorts. Plasma p-tau217, p-tau181, and neurofilament light chain (NfL) assays are being validated for use in clinical settings with limited access to CSF testing.

Genetic Biomarkers:
Research on genetic risk factors in Brazilian populations has identified both known risk variants and novel associations specific to admixed Latin American populations.

Gene Therapy

Gene therapy represents an emerging therapeutic approach in Brazil, with several groups and companies developing programs targeting neurodegenerative diseases[@duarte2024].

AAV Vectors:
Brazilian researchers have established capabilities in adeno-associated virus (AAV) vector development for CNS gene delivery. Research programs are exploring AAV-mediated expression of neurotrophic factors including GDNF and BDNF for Parkinson's disease.

Gene Editing:
CRISPR-based gene editing approaches are being developed for both gain-of-function and loss-of-function mutations in familial neurodegenerative disease. These programs aim to develop precision therapies for patients with specific genetic mutations.

Clinical Trial Activity

Brazil has become an increasingly important location for clinical trials in neurodegenerative diseases, offering advantages including large patient populations, established clinical infrastructure, and favorable regulatory pathways[@barroso2023].

Current Trial Landscape

| Phase | AD Trials | PD Trials | Other Neurodegenerative |
|-------|-----------|-----------|------------------------|
| Phase 1 | 2 | 1 | 1 |
| Phase 2 | 5 | 3 | 2 |
| Phase 3 | 8 | 5 | 3 |

Alzheimer's Disease:
Brazilian sites are participating in numerous anti-amyloid antibody trials, including studies of lecanemab, donanemab, and gantenerumab. These trials have contributed to the global development programs of these disease-modifying therapies.

Parkinson's Disease:
Clinical trials in Parkinson's disease include disease-modifying therapies targeting alpha-synuclein aggregation, LRRK2 inhibitors, and gene therapy approaches. Brazilian sites have contributed significantly to enrollment in these studies.

Other Conditions:
Clinical trials for amyotrophic lateral sclerosis (ALS), Huntington's disease, and frontotemporal dementia are also active in Brazil, providing patients with access to experimental therapies.

Notable Trial Programs

Anti-Amyloid Antibodies:
Brazilian sites have participated in pivotal trials for anti-amyloid antibodies, with several sites recognized for high enrollment and data quality. The experience gained in these trials has established Brazil as a preferred region for Alzheimer's disease clinical development.

LRRK2 Inhibitors:
Several LRRK2 inhibitor programs have included Brazilian clinical sites, leveraging the relatively high frequency of LRRK2 mutations in Brazilian Parkinson's disease patients.

Cell Therapy Trials:
Brazilian companies including Cryopraxis have conducted cell therapy trials in Parkinson's disease patients, with early data demonstrating safety and preliminary efficacy signals.

International Collaborations

Brazilian biotech companies and research institutions maintain active international collaborations that provide access to expertise, funding, and global markets.

Pharmaceutical Partnerships

Roche: Multiple collaborations including clinical trial execution and biomarker validation programs.

Pfizer: Partnership on clinical development programs in Alzheimer's disease, including site selection and patient recruitment.

Novartis: Several collaborations including both early-stage research and clinical development.

Academic Collaborations

DIAN (Dominantly Inherited Alzheimer Network): USP participation in this international consortium for early-onset Alzheimer's disease research.

GERAD (Genetic Epidemiology of Alzheimer's Disease): Collaboration on genetic studies in Brazilian populations.

Global Parkinson's Genetics Program (GP2): Participation in this effort to characterize PD genetics globally.

Consortium Participation

Latin American Alzheimer's Alliance: Regional collaboration among Latin American countries for Alzheimer's research and clinical development.

REGNECOGNITION: European-Latin American network for cognitive disorders research.

Funding and Investment Landscape

Public Funding

The Brazilian government provides significant funding for neurodegenerative disease research through multiple agencies:

FAPESP (São Paulo Research Foundation): Leading funding agency supporting basic and translational research in neurodegeneration through research grants, innovation programs, and fellowship support.

CNPq (National Council for Scientific and Technological Development): Federal funding agency supporting research across all scientific domains, including neuroscience.

FINEP (Funding Authority for Studies and Projects): Federal funding for applied research and innovation, including support for biotech company development.

Private Investment

Private investment in Brazilian neurodegeneration biotech is growing but remains limited compared to the United States and Europe. Venture capital activity has increased in recent years, with some success in Series A and later funding rounds.

Notable Investments:

Recepta Biopharma: Series B funding for oncology and neuroscience pipeline development
Cryopraxis: Strategic partnership with international pharmaceutical company
Herbarium: Parent company investment in R&D for pharmaceutical development

Challenges and Opportunities

Challenges

Funding: Limited venture capital for biotech, particularly for early-stage companies. Most VC funding goes to later-stage companies with validated programs.

Regulatory: ANVISA approval processes can be lengthy, though recent reforms have improved timelines for innovative therapies.

Manufacturing: Local GMP production capacity is limited, particularly for advanced therapy medicinal products (ATMPs) including cell therapies.

Market size: Domestic market limitations require companies to pursue international markets early in their development.

Talent: Competition for experienced researchers and development staff, particularly in translational and clinical roles.

Opportunities

Biodiversity: Unique natural product libraries from Brazilian flora represent a differentiated drug discovery resource.

Academic talent: Well-trained neuroscience researchers from Brazilian universities provide a strong foundation for biotech development.

Clinical infrastructure: Large patient populations and established clinical sites enable efficient clinical trial execution.

Regional hub: Gateway to Latin American markets, with potential to expand across the region.

Regulatory convergence: Alignment with international regulatory standards facilitates global development programs.

Future Directions

Brazilian neurodegeneration biotech is evolving to address both domestic and global markets:

Emerging Areas

Gene Therapy: Several groups are developing gene therapy approaches for neurodegenerative diseases, leveraging local expertise in AAV vector development and gene editing.

AI/ML: Computational biology approaches are being applied to drug discovery, including machine learning for target identification and compound optimization.

Precision Medicine: Genetic testing integration and biomarker-driven patient selection are enabling more targeted therapeutic development.

Digital Health: Remote monitoring tools and digital biomarkers are being developed for clinical trial endpoints and patient management.

Strategic Priorities

International partnerships: Building global partnerships for co-development and commercialization

Regulatory expertise: Strengthening regulatory capabilities for global submissions

Manufacturing scale-up: Developing local GMP capabilities for advanced therapies

Talent development: Training the next generation of drug developers and researchers

Cross-References

[Latin American Neurodegeneration Biotech](/companies/latin-american-neurodegeneration-biotech)
[CBIO Brazil](/companies/cbio-brazil)
[Recepta Biopharma](/companies/recepta-biopharma)
[Cryopraxis](/companies/cryopraxis)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Neurodegeneration](/diseases/neurodegeneration)

[Neuroinflammation Pathways](/mechanisms/neuroinflammation)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Alpha-synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)

[Brazilian Neurology Research](/organizations/brazilian-neurology-society)
[Stem Cell Therapy for Neurodegeneration](/research/stem-cell-therapy-neurodegeneration)
[Natural Products Drug Discovery](/research/natural-products-neurodegeneration)

Summary

Brazilian biotechnology companies are contributing to neurodegenerative disease research through stem cell therapy, natural product development, biomarker research, and clinical trial execution. While the sector is still emerging, strong academic institutions and growing pharma partnerships position Brazil as an important hub for neurodegeneration research in Latin America.

The ecosystem includes both established companies like Recepta Biopharma and Cryopraxis advancing clinical-stage programs, and academic institutions generating foundational knowledge and trained researchers. Key strengths include expertise in stem cell therapy, access to unique natural product libraries, and established clinical trial infrastructure.

Challenges remain, particularly around funding and manufacturing capabilities, but the sector is evolving rapidly. With continued investment and strategic partnerships, Brazilian biotech companies have the potential to make significant contributions to global neurodegeneration drug development.

slug	companies-brazilian-neurodegeneration-biotech
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5729a21018b9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-brazilian-neurodegeneration-biotech'}
_schema_version	1

📗 Cite This Artifact

Brazilian Neurodegeneration Biotech Companies

Overview

Overview

Key Companies

Recepta Biopharma

Brazilian Brain Institute (IBN)

Herbarium (Grupo Boticário)

Cryopraxis

Astellas Brazil

Latin American Neurodegeneration Research Network (LANDRn)

Academic Research Centers

University of São Paulo (USP) - Department of Neurology

Federal University of Rio de Janeiro (UFRJ) - Neuroscience Institute

Federal University of Minas Gerais (UFMG) - Neurology Department

Therapeutic Approaches

Stem Cell Therapy

Natural Products

Biomarker Development

Gene Therapy

Clinical Trial Activity

Current Trial Landscape

Notable Trial Programs

International Collaborations

Pharmaceutical Partnerships

Academic Collaborations

Consortium Participation

Funding and Investment Landscape

Public Funding

Private Investment

Challenges and Opportunities

Challenges

Opportunities

Future Directions

Emerging Areas

Strategic Priorities

Cross-References

Summary

See Also

💬 Discussion

📗 Cite This Artifact

Brazilian Neurodegeneration Biotech Companies

Overview

Overview

Key Companies

Recepta Biopharma

Brazilian Brain Institute (IBN)

Herbarium (Grupo Boticário)

Cryopraxis

Astellas Brazil

Latin American Neurodegeneration Research Network (LANDRn)

Academic Research Centers

University of São Paulo (USP) - Department of Neurology

Federal University of Rio de Janeiro (UFRJ) - Neuroscience Institute

Federal University of Minas Gerais (UFMG) - Neurology Department

Therapeutic Approaches

Stem Cell Therapy

Natural Products

Biomarker Development

Gene Therapy

Clinical Trial Activity

Current Trial Landscape

Notable Trial Programs

International Collaborations

Pharmaceutical Partnerships

Academic Collaborations

Consortium Participation

Funding and Investment Landscape

Public Funding

Private Investment

Challenges and Opportunities

Challenges

Opportunities

Future Directions

Emerging Areas

Strategic Priorities

Cross-References

Related Companies

Related Diseases

Related Mechanisms

Related Research

Summary

See Also

💬 Discussion